SBIR/STTR Research Award
The IRIS-HIV assay, a point-of-care, multiplex serological assay to identify HIV Infection and Vaccine-Induced Seropositivity
Award amount
$299,855Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Intuitive Biosciences, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NTJMYEMGRKH1
- Solicitation number
- PHS-2022-1
- Topic code
- 103
Research abstract
Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity: Several years of clinical trials have revealed that some HIV vaccines can elicit long-lasting (rt15 years) serological immune responses that can be confused with HIV infection in common diagnostic tests. This phenomenon is known as vaccine-induced sero-reactivity or sero-positivity (VISR/VISP). The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to VISP, with high sensitivity and specificity.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Developing virtual reality programs to address social skills deficits in youth with ADHD
- Commercialization readiness of motion-robust brain MRI for pediatric healthcare
- Improved flow cytometry panel design with a novel automated panel design system
- Time-resolved laser speckle contrast imaging of resting-state functional connectivity in neonatal brain
- Using Machine Learning and Sensing to Contextualize Hyperactivity Measurement on Wearable Devices
Research funding history
2 SBIR/STTR records share this UEI (2022–2023). Reported award amounts total $606,061. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services